Press enter to see results or esc to cancel.

Synendos Therapeutics

A spin-out of the University of Bern and the drug discovery consortium NCCR TransCure, Synendos Therapeutics is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS) disorders. Synendos’ …

Continue Reading

SparingVision

SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision aims to deliver new treatments that go beyond single gene correction therapies for patients affected by Inherited Retinal Diseases (IRDs) such as Retinitis …

Continue Reading

OxThera

OxThera is on a mission is to bring novel treatment options to rare kidney disease. The company holds proprietary rights to pharmaceutical preparations and their use for the treatment of hyperoxaluria. Oxabact has received orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria (PH). Oxabact is an oral product …

Continue Reading

AM-Pharma

AM-Pharma is a clinical-stage biopharmaceutical company developing a treatment for sepsis-associated acute kidney injury (SA-AKI) – recombinant human alkaline phosphatase therapeutic. The company is focused on the successful execution of its Phase III REVIVAL pivotal trial while continuing to build an organization committed to using its insight and knowledge for other severe medical conditions, including …

Continue Reading